Dr. Samuel C. Blackman is a physician-scientist trained in pediatric hematology-oncology and pediatric neuro-oncology. He joined Mavu in 2018 as head of clinical development. For over 10 years he has been focused on the early clinical development of novel cancer therapeutics and has held various positions of increasing responsibility within the pharmaceutical and biotechnology industry. He has led or overseen over a dozen early clinical development programs across a range of therapeutic modalities, including small molecules, antibody-drug conjugates, and cellular therapeutics.
Prior to this role, he was Senior Vice President and Head of Clinical Development at Silverback Therapeutics where he was responsible for end-to-end clinical development of novel immunotherapeutics for solid tumors. Before joining Silverback, Dr. Blackman was an executive at Juno Therapeutics he was responsible for leading the clinical development of novel cellular immunotherapeutics for leukemia, including chimeric antigen receptor (CAR) T cell therapies and high-affinity T cell receptor (TCR) therapies. He was Executive Director and Head of Translational Medicine and Early Development at Seattle Genetics and oversaw a portfolio of early-stage antibody-drug conjugate programs. At GlaxoSmithKline, he was responsible for multiple early development programs as well as the design and implementation of the pediatric development strategy for dabrafenib and trametinib, which represent two of the earliest industry-sponsored “basket trials” for pediatric cancer.
Dr. Blackman is a graduate of the pediatric hematology/oncology fellowship program at the Dana-Farber Cancer Institute and Children’s Hospital Boston, and the pediatric residency program at Cincinnati Children’s Hospital Medical Center. He received his M.D. and Ph.D. degrees at the University of Illinois at Chicago College of Medicine and Department of Pharmacology, and his undergraduate degree in philosophy from the University of Chicago.